Business Context and Reporting Period
This Form 8-K was filed by Blue Water Vaccines Inc. on April 19, 2022, reporting events dated April 13, 2022. The request metadata identifies Onconetix, Inc., but the filing’s registrant is Blue Water Vaccines Inc.; this entity discrepancy should be verified.
The filing reports the pricing and closing of a private placement of equity securities and related warrants. Blue Water Vaccines was an emerging growth company, with common stock trading on Nasdaq under the symbol BWV.
Key Financial and Capitalization Metrics
- Gross proceeds were approximately $8.0 million, before placement-agent fees and other offering expenses.
- The company issued 590,406 shares of common stock and pre-funded warrants exercisable for an aggregate of 590,406 common shares.
- Purchasers also received preferred investment options to purchase up to 1,180,812 common shares.
- The purchase price was $6.775 per share and associated preferred investment option, or $6.774 per pre-funded warrant and associated preferred investment option.
- Pre-funded warrants have a $0.001 exercise price, are exercisable beginning April 19, 2022, and terminate April 20, 2026.
- Preferred investment options have a $6.65 exercise price, are exercisable beginning April 19, 2022, and terminate April 20, 2026. They may generally be exercised on a cashless basis if an effective resale registration statement is unavailable.
- H.C. Wainwright & Co. received a cash fee equal to 7.5% of gross proceeds, a 1.0% management fee, reimbursement of certain expenses up to $85,000, and warrants for up to 70,849 common shares.
- Wainwright warrants have an exercise price of $8.46875 per share and terminate on terms substantially similar to the preferred investment options.
- The filing does not provide revenue, net income, operating cash flow, cash balances, margins, debt balances, or liquidity ratios.
Material Changes Versus the Prior Comparable Period
The filing does not provide comparative operating or financial results. The material changes disclosed are the receipt of approximately $8.0 million of gross financing proceeds and the issuance of common stock, pre-funded warrants, preferred investment options, and placement-agent warrants, which may result in future dilution.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Net proceeds are restricted for working capital purposes and may not be used for debt repayment, except for ordinary-course trade payables, common-stock redemptions, or settlement of outstanding litigation, subject to the agreement’s terms.
- The company agreed to specified limitations on additional equity offerings and variable-rate transactions for defined periods following the offering and registration effectiveness.
- The company must file a resale registration statement by the 20th calendar day after April 13, 2022, and generally obtain effectiveness within 45 days, or 75 days if subject to full SEC review.
- If defined registration-related events restrict resale for specified periods, the company may owe monthly liquidated damages equal to 2.0% of each purchaser’s aggregate subscription amount.
- The securities were sold in unregistered transactions under Section 4(a)(2) and Rule 506 of Regulation D to accredited investors.
- The filing contains no operating guidance, revenue outlook, profitability forecast, or management discussion of business performance.
Important Facts for Investors to Verify
- Confirm whether the relevant issuer is Blue Water Vaccines Inc. or Onconetix, Inc.; the filing text identifies Blue Water Vaccines Inc.
- Verify the actual net proceeds after placement-agent fees and other offering expenses.
- Review the company’s capitalization after issuance and the potential dilution from all warrants and preferred investment options.
- Confirm the filing and effectiveness status of the required resale registration statement and any resulting liquidated-damages exposure.
- Review the filed purchase agreement, registration rights agreement, warrant forms, and offering press release for complete terms and adjustments.
- Note the apparent timing distinction: the agreement and pricing were dated April 13, while the closing and securities issuance occurred April 19, 2022.